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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERThe Role of Monocytes in Angiogenesis and Atherosclerosis 1
Anthony S. Jaipersad, Gregory Y. H. Lip, Stanley Silverman, Eduard Shantsila
Monocytes are intimately involved in tissue damage and repair, and an imbalance of these
processes may have detrimental consequences for plaque development and stability.
Monocytes are comprised of distinct subsets identiﬁed by cell surface markers; these subsets
have distinct functional characteristics, and this heterogeneity may be relevant to the
angiogenic processes in atherosclerosis. Jaipersad and colleagues present an overview of the
available evidence supporting a role for monocytes in angiogenesis.VIEWPOINT VIEWPOINTThe Disconnect Between Guidelines, Appropriate Use Criteria,
and Reimbursement Coverage Decisions12Richard I. Fogel, Andrew E. Epstein, N. A. Mark Estes III, Bruce D. Lindsay, John P. DiMarco,
Mark S. Kremers, Suraj Kapa, Ralph G. Brindis, Andrea M. Russo
Recently, the American College of Cardiology Foundation, in collaboration with the Heart
Rhythm Society, published appropriate use criteria (AUC) for implantable cardioverter-
deﬁbrillators (ICDs) and cardiac resynchronization therapy (CRT). These criteria were
developed to critically review clinical situations that may warrant implantation of an ICD or
CRT device. The writing committee recognized that some of the scenarios that were deemed
as “appropriate” or “may be appropriate” were discordant with the clinical requirements of
many payers, including the Medicare National Coverage Determination (NCD). To charge
Medicare for a procedure that is not covered by the NCD may be construed as fraud.
Discordance among the guidelines, the AUC, and the NCD causes clinicians to have the
difﬁcult dilemma of trying to do the “right thing” for their patients, but recognizing that the
“right thing” may not be covered by the payer or insurer.(continued on page A-37)
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Gregg W. Stone, Tim Clayton, Efthymios N. Deliargyris, Jayne Prats, Roxana Mehran, Stuart J. Pocock
Stone and colleagues sought to determine whether the reduction in cardiac mortality in
patients undergoing primary percutaneous coronary intervention with bivalirudin compared
with unfractionated heparin plus a glycoprotein IIb/IIIa inhibitor in the HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction)
trial can be fully attributed to reduced bleeding. Bivalirudin resulted in lower 3-year rates of
major bleeding (6.9% vs. 10.5%) and cardiac mortality (2.9% vs. 5.1%). The 3-year cardiac
mortality was reduced in bivalirudin-treated patients with major bleeding (5.8% vs. 14.6%)
and without major bleeding (2.6% vs. 3.8%). In a fully-adjusted multivariable model
accounting for major bleeding and other adverse events, bivalirudin was still associated with a
43% reduction in 3-year cardiac mortality. The reduction in cardiac mortality with bivalirudin
in ST-segment elevation myocardial infarction patients can only partly be attributed to the
prevention of bleeding.CORONARY SURGERYSOCS1 Prevents Graft Arteriosclerosis 21
Lingfeng Qin, Qunhua Huang, Haifeng Zhang, Renjing Liu, George Tellides, Wang Min, Luyang Yu
Qin and colleagues sought to determine the role of suppressor of cytokine signaling 1
(SOCS1) in graft arteriosclerosis (GA). SOCS1, a negative regulator of cytokine signaling, is
highly expressed in endothelial cells (ECs) and may prevent endothelial inﬂammatory
responses. Coronary arteries with GA, with atherosclerosis, or without disease were collected
for histological analysis. SOCS1 knockout mice or vascular endothelial SOCS1 transgenic
mice were used in an aorta transplant model of GA. A dramatic, but speciﬁc, reduction of
endothelial SOCS1 was observed in human GA and atherosclerosis specimens. SOCS1
deletion in mice resulted in basal EC dysfunction. Further studies conﬁrmed the importance
of SOCS1 in preventing GA progression by preserving endothelial function and attenuating
cytokine-induced adhesion molecule expression in vascular endothelium.
Editorial Comment: Roel A. de Weger, p. 30(continued on page A-38)
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Mark A. Hlatky, Derek B. Boothroyd, Bruce A. Reitz, David A. Shilane, Laurence C. Baker, Alan S. Go
The effect of internal mammary artery (IMA) grafting on major clinical outcomes has never
been tested in a large randomized trial. Hlatky and colleagues identiﬁed Medicare
beneﬁciaries who underwent an isolated multivessel coronary artery bypass graft between
1988 and 2008. IMA use rose slowly from 31% in 1988 to 91% in 2008, with persistent wide
geographic variations. Among 60,896 propensity score-matched patients, IMA use was
associated with lower all-cause mortality (adjusted hazard ratio [HR]: 0.77), lower death or
MI (adjusted HR: 0.77), and fewer repeat revascularizations over 5 years.HEART RHYTHM DISORDERSLow-Energy Multistage Therapy for AF Cardioversion 40Ajit H. Janardhan, Sarah R. Gutbrod, Wenwen Li, Di Lang, Richard B. Schuessler, Igor R. Eﬁmov
Previous attempts to cardiovert atrial ﬁbrillation (AF) using an implantable device were
limited by the pain caused by high-energy, single biphasic shocks (BPS). Janardhan and
colleagues tested an implantable device that uses multistage electrotherapy (MSE) to
terminate AF in a canine model. Self-sustaining AF was induced by high-rate right atrial
pacing. MSE terminated AF with signiﬁcantly less energy and signiﬁcantly lower peak
voltage than BPS. Low-energy MSE, which uses a short burst of low-energy impulse,
may be the basis for a painless, device-based AF therapy.
Editorial Comment: Edward P. Gerstenfeld, Thomas H. Everett IV, p. 49(continued on page A-39)
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Ziad Hijazi, Lars Wallentin, Agneta Siegbahn, Ulrika Andersson, John H. Alexander, Dan Atar,
Bernard J. Gersh, Michael Hanna, Veli Pekka Harjola, John D. Horowitz, Steen Husted,
Elaine M. Hylek, Renato D. Lopes, John J. V. McMurray, Christopher B. Granger,
on behalf of the ARISTOTLE Investigators
Hijazi and colleagues used data from the ARISTOTLE (Apixaban for the Prevention of
Stroke in Subjects With Atrial Fibrillation) trial to evaluate the prognostic value of high-
sensitivity troponin T (hs-TnT) for predicting the risk of stroke in patients with atrial
ﬁbrillation (AF). Baseline hs-TnT concentrations were measured in nearly 15,000 subjects
with AF randomized to apixaban or warfarin. The annual rates of stroke or systemic
embolism ranged from 0.87% in the lowest hs-TnT quartile to 2.13% in the highest quartile.
For cardiac death, the annual rates ranged from 0.46% to 4.24%, and for major bleeding, they
ranged from 1.26% to 4.21%. Adding hs-TnT levels to the CHA2DS2VASc score improved
the C-statistic for stroke or systemic embolism, cardiac death, and major bleeding. hs-TnT
level is independently associated with the risk of stroke, cardiac death, and major bleeding.CARDIAC IMAGINGStatins for Prevention of Contrast-Induced Acute Kidney Injury 62
Yaling Han, Guoying Zhu, Lixian Han, Fengxia Hou, Weijian Huang, Huiliang Liu, Jihong Gan,
Tiemin Jiang, Xiaoyan Li, Wei Wang, Shifang Ding, Shaobin Jia, Weifeng Shen, Dongmei Wang,
Ling Sun, Jian Qiu, Xiaozeng Wang, Yi Li, Jie Deng, Jing Li, Kai Xu, Bo Xu, Roxana Mehran,
Yong Huo
Han and colleagues investigated the utility of statins for preventing contrast-induced acute
kidney injury (CI-AKI) in patients with diabetes mellitus (DM) and chronic kidney disease
(CKD). Almost 3,000 subjects with DM and stage 2 to 3 CKD who were to undergo
angiography were randomized to rosuvastatin 10 mg/day for 5 days (2 days before to 3 days
after procedure) or standard of care. Patients randomized to the rosuvastatin group had a
signiﬁcantly lower incidence of CI-AKI compared with control patients (2.3% vs. 3.9%; odds
ratio: 0.58) and had lower rates of worsening heart failure over the next 30 days. Rosuvastatin
signiﬁcantly reduced the risk of CI-AKI in patients with DM and CKD undergoing arterial
angiography.(continued on page A-40)
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Mario Leoncini, Anna Toso, Mauro Maioli, Francesco Tropeano, Simona Villani, Francesco Bellandi
Leoncini and colleagues studied whether, in addition to standard preventive measures,
high-dose rosuvastatin protects against contrast-induced acute kidney injury (CI-AKI).
Consecutive, statin-naive patients with acute coronary syndromes (ACS) scheduled for an
early invasive strategy were randomly assigned to receive rosuvastatin or no statin treatment.
The incidence of CI-AKI was signiﬁcantly lower in the statin group (adjusted odds ratio:
0.38). The beneﬁts against CI-AKI were consistent in all of the pre-speciﬁed risk categories.
Statin therapy was also associated with a lower rate of death and nonfatal myocardial
infarction during follow-up. High-dose rosuvastatin in patients with ACS scheduled for early
invasive procedure can prevent CI-AKI and improve short-term clinical outcomes.
Editorial Comment: Martin A. Alpert, p. 80
